Metabolic

The metabolic category is the most clinically advanced area in the entire peptide landscape. The GLP-1 receptor agonist revolution has transformed the treatment of obesity and type 2 diabetes, producing FDA-approved medications with unprecedented efficacy in weight loss and metabolic improvement. These compounds work by mimicking incretin hormones — gut-derived peptides that signal satiety, slow gastric emptying, enhance insulin secretion, and reduce glucagon release. The clinical data behind these drugs is extensive, with large randomized controlled trials demonstrating sustained weight loss of 15-25% of body weight alongside improvements in cardiovascular risk markers, blood pressure, and inflammatory biomarkers.

The progression from single to multi-receptor agonism defines the trajectory of this drug class. Semaglutide (Ozempic, Wegovy) is a pure GLP-1 receptor agonist that achieves approximately 15-17% weight loss in clinical trials. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that reaches approximately 20-22% weight loss — the addition of GIP receptor activity providing additive metabolic benefits. Retatrutide pushes further as a triple agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously, with Phase 2 trial data showing up to 24% weight loss at 48 weeks. Orforglipron represents the next frontier: a small-molecule, non-peptide GLP-1 receptor agonist that can be taken as a daily oral pill rather than a weekly injection, potentially transforming access and adherence.

Beyond the incretin class, this category includes mechanistically distinct compounds. MOTS-c is a mitochondrial-derived peptide that functions as an exercise mimetic, activating AMPK (the cellular energy sensor) and improving glucose disposal in skeletal muscle. It is being studied for its potential to replicate some metabolic benefits of physical exercise at the cellular level. 5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor — NNMT is an enzyme upregulated in obesity that contributes to metabolic dysfunction by depleting the NAD+ pool. AOD-9604 also appears in this category for its targeted fat-metabolizing properties.

The clinical maturity of this category sets it apart. Semaglutide and tirzepatide are fully FDA-approved with Phase 3 trial data involving tens of thousands of patients. Retatrutide and orforglipron are in late-stage clinical development. This stands in stark contrast to most other peptide categories where preclinical data predominates. The main practical considerations involve managing gastrointestinal side effects (nausea, which typically attenuates), preserving lean mass during rapid weight loss, and the emerging question of long-term maintenance therapy.